Phase II study of azotomycin (NSC-56654).
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D001391:Azo Compounds